浙江经典无性人体固定头躯干模型天津有机磷中毒模拟人,安徽高仿真超声、X线引导经皮穿刺肾镜训练模型,湖北未组装的附肌肉起止点散骨模型,上海微观解剖肾脏模型,湖北168cm成人头骨左半边肌肉着色右半边骨性色分模型带颈部肌肉模型,江苏深静脉穿刺模型,新疆全功能旋转式动脉手臂穿刺训练模型

The Washington Redskins are changing their name.According to the Sports Business Journal's John Ourand, the organization will announce the change on Monday. 164

The suspect in the Pittsburgh synagogue massacre faces 44 federal charges -- most of them death penalty offenses -- in the slaying of 11 worshippers during last weekend's Shabbat services, according to a grand jury filing released Wednesday.Included are 11 counts each of obstruction of free exercise of religious belief resulting in death and use of a firearm to commit murder during a crime of violence.Thirty-two of the charges are punishable by death, according to the indictment.The suspected gunman, Robert Bowers, is accused of targeting the Saturday morning services at the Tree of Life synagogue after making anti-Semitic posts online. 652

The US stock market sank deeper into the red following sluggish economic reports on Monday and bad news from a couple of blue-chip giants.The Dow fell 600 points by late afternoon, or 2.6%. The S&P 500 lost 2.6% and retreated to its lowest level of the year. And the Nasdaq joined the Dow & S&P 500 in negative territory for 2018. All three indexes have plunged about 7% so far this December.The Dow closed down 507 points for the day.And the Russell 2000 index of small-cap stocks tumbled into a bear market, marking a 20% decline from the record highs notched in late August.A weaker reading from the New York Federal Reserve about manufacturing in the Empire State and a drop in confidence from the nation's homebuilders weighed on the markets."Investors are zeroing in on this idea of slower growth for 2019," said Michael Arone, chief investment strategist at State Street Global Advisors. "More people are worried about a recession in late 2019 or 2020."The political noise in Washington isn't helping either. President Trump, in a tweet Monday morning, repeated his criticism of the Federal Reserve for its recent rate hikes. The Fed meets Wednesday and is widely expected to raise rates again.But Trump tweeted that "it is incredible that with a very strong dollar and virtually no inflation, the outside world blowing up around us, Paris is burning and China way down, the Fed is even considering yet another interest rate hike. Take the Victory!"The Fed is supposed to be politically independent. Any evidence that it might be swayed by attacks from Trump could unnerve the markets."If the Fed doesn't raise rates it will look like it's succumbing to the bullying of Trump's tweets," Arone said.But Nancy Perez, managing director at Boston Private, said the Fed is likely to slow down its pace of rate hikes in 2019 simply because the economy is slowing, not because of pressure from Trump.Perez added that the recent market turmoil is justified because investors are readjusting to this fact."We have been getting a bump in profit margins due to lower taxes but the earnings growth itself is not sustainable," Perez said. "Projections will come down and volatility will continue." 2247

The Trump Administration pushed through a million contract to study whether the active ingredient in Pepcid is an effective treatment for Covid-19. That contract is now under scrutiny after a government whistleblower accused a senior administration official of rushing the deal through without the scientific oversight necessary for such a large federal award. The Food and Drug Administration gave the clinical trial speedy approval even as a top agency official worried that daily injections of high doses of famotidine for already sick patients pushed the levels of what was considered safe “to the limits,” internal government emails show. And the doctors who initially pushed the Pepcid idea are locked in a battle for credit and sniping over allegations of scientific misconduct.The origins of the interest in famotidine are under dispute, but there were reports out of China that patients who took the drug survived the virus, while patients who took other heartburn medications were not surviving. Initial observational studies in the U.S. were promising, however scientists urged more research was needed. Meantime, the trial itself that was part of the million contract is on pause due to a shortage of hospitalized COVID-19 patients in New York, delaying it indefinitely. A vaccine or effective treatment could be available before the study is complete. 1380

The United Kingdom says it will be the first to conduct COVID-19 vaccine human challenge trials.It's different than other vaccine studies. People will be deliberately infected with the virus, which speeds up the research process.Pending approval, the process will start in January at a London hospital. It will require about 90 healthy young adults between the ages of 18 and 30.The group 1 Day Sooner has recruited from all over the world, including 3,000 Britons.“If the vaccine works, then ideally, people don't get infected and if people do, then they will be closely monitored and treated, but because these are young and healthy people taking part in the trial, I think, researchers feel comfortable doing so because the risks of death are on par with something like kidney donation for people who are young and healthy,” said Abie Rohrig with 1 Day Sooner.Before researchers test the vaccine, they'll do a characterization study. That's where volunteers are infected by getting a vaccine to determine the right amount of virus to give during the trial.Because of the risk, 1 Day Sooner is advocating for the entire process to be made public.Results could come in May. Even though that's likely after other COVID-19 vaccines are licensed, it's still important because we need billions of doses and because of the unique data human challenge trials provide.“Researchers can understand how the virus works in the human body. They can understand the biological markers of immunity. In fact, much of our understanding of other types of coronaviruses come from challenge studies that were conducted in the 1960s in Britain,” said Rohrig.Human challenge volunteers are paid and monitored for at least a year after. 1722